BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21784641)

  • 1. Experimental human pneumococcal carriage models for vaccine research.
    Ferreira DM; Jambo KC; Gordon SB
    Trends Microbiol; 2011 Sep; 19(9):464-70. PubMed ID: 21784641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children.
    Tocheva AS; Jefferies JM; Rubery H; Bennett J; Afimeke G; Garland J; Christodoulides M; Faust SN; Clarke SC
    Vaccine; 2011 Jun; 29(26):4400-4. PubMed ID: 21504773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
    Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
    Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis.
    Pavia M; Bianco A; Nobile CG; Marinelli P; Angelillo IF
    Pediatrics; 2009 Jun; 123(6):e1103-10. PubMed ID: 19482744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers.
    Dagan R; Givon-Lavi N; Zamir O; Sikuler-Cohen M; Guy L; Janco J; Yagupsky P; Fraser D
    J Infect Dis; 2002 Apr; 185(7):927-36. PubMed ID: 11920317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species.
    Pletz MW; Maus U; Krug N; Welte T; Lode H
    Int J Antimicrob Agents; 2008 Sep; 32(3):199-206. PubMed ID: 18378430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 introduction in France.
    Cohen R; Levy C; Bonnet E; Grondin S; Desvignes V; Lecuyer A; Fritzell B; Varon E
    Vaccine; 2010 Aug; 28(37):6114-21. PubMed ID: 19490958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serological criteria and carriage measurement for evaluation of new pneumococcal vaccines.
    Principi N; Esposito S
    Hum Vaccin Immunother; 2015; 11(6):1494-500. PubMed ID: 25970715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of carriage and transmission of Streptococcus pneumoniae: the beneficial "side effect" of pneumococcal conjugate vaccine.
    Azzari C; Resti M
    Clin Infect Dis; 2008 Oct; 47(8):997-9. PubMed ID: 18781870
    [No Abstract]   [Full Text] [Related]  

  • 11. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members.
    Millar EV; Watt JP; Bronsdon MA; Dallas J; Reid R; Santosham M; O'Brien KL
    Clin Infect Dis; 2008 Oct; 47(8):989-96. PubMed ID: 18781875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers.
    Dagan R; Givon-Lavi N; Zamir O; Fraser D
    Pediatr Infect Dis J; 2003 Jun; 22(6):532-40. PubMed ID: 12799510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae.
    Dagan R
    Clin Microbiol Infect; 2009 Apr; 15 Suppl 3():16-20. PubMed ID: 19366365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The fundamental link between pneumococcal carriage and disease.
    Simell B; Auranen K; Käyhty H; Goldblatt D; Dagan R; O'Brien KL;
    Expert Rev Vaccines; 2012 Jul; 11(7):841-55. PubMed ID: 22913260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The volatile nature of pneumococcal serotype epidemiology: potential for misinterpretation.
    Black S
    Pediatr Infect Dis J; 2010 Apr; 29(4):301-3. PubMed ID: 19935444
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population.
    Millar EV; O'Brien KL; Watt JP; Bronsdon MA; Dallas J; Whitney CG; Reid R; Santosham M
    Clin Infect Dis; 2006 Jul; 43(1):8-15. PubMed ID: 16758412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of pneumococcal conjugate vaccines on otitis media-can we extrapolate to pneumonia?
    Dagan R
    Vaccine; 2008 Jun; 26 Suppl 2():B16-8. PubMed ID: 18793601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
    Zangeneh TT; Baracco G; Al-Tawfiq JA
    Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination.
    Väkeväinen M; Soininen A; Lucero M; Nohynek H; Auranen K; Mäkelä PH; Williams G; Käyhty H;
    J Pediatr; 2010 Nov; 157(5):778-83.e1. PubMed ID: 20547399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a pneumococcal conjugate vaccine against acute otitis media.
    Eskola J; Kilpi T; Palmu A; Jokinen J; Haapakoski J; Herva E; Takala A; Käyhty H; Karma P; Kohberger R; Siber G; Mäkelä PH;
    N Engl J Med; 2001 Feb; 344(6):403-9. PubMed ID: 11172176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.